Clinical trials: Uric Acid
Cardiovascular Diseases, Uric Acid
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in…
- Trial name
- ALL-VASCOR (NCT05943821)
- Testing
- Allopurinol 200 mg, Optional intervention
- Where
- Poland
- Volunteers
- 1,116 people
- Sponsor
- Poznan University of Medical Sciences
Hypertension
The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients
Hypertension is one of the most common cardiovascular diseases, which is a major risk factor for stroke and cardiovascular events.
- Trial name
- NCT02563405
- Testing
- Doxazosin, Nifedipine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Inflammation
Montmorency Cherry Juice and Uric Acid Metabolism
Cherries have been show to possess the ability to reduce uric acid concentrations and inflammation. Tart Montmorency cherries possess a higher concentration of the plant compounds than other cherries and hence makes the…
- Trial name
- NCT01825070
- Testing
- Montmorency cherry concentrate
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Northumbria University
Alcohols, Cardiovascular Diseases
Postprandial Effect of Chinese Tea Flavor Liquor on Selected CVD Risk Factors
Background: human studies of Chinese liquor are sparse. we hypothesis that Chinese Tea Flavor liquor may be beneficial to CVD risk factors postprandially.
- Trial name
- TFL (NCT01264666)
- Testing
- Chinese tea flavor liquor, Chinese Meijiao liquor, Water control
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
Gout
Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit
The objective of this research is to evaluate the correlation between DECT and US explorations performed in a routine clinical setting for the measurement of change in tophus size in gout patients after 24 months of treatment.
- Trial name
- GOUT (NCT03162341)
- Testing
- ultrasonography, DECT
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Lille Catholic University
Gout
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the…
- Trial name
- RELEASE (NCT07280156)
- Testing
- PRX-115, Methotrexate (MTX)
- Where
- 35 sites in United States, Georgia and 1 more
- Volunteers
- 150 people
- Sponsor
- Protalix
Systolic and Diastolic Blood Pressure Levels, Uric Acid Levels
Hyperuricemia on Hypertension and Metabolic Syndrome
The purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.
- Conditions
- Systolic and Diastolic Blood Pressure Levels, Uric Acid Levels, Metabolic Syndrome Parameters, Hepatic Enzymes
- Trial name
- NCT01157936
- Testing
- Allopurinol
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Acute Gouty Arthritis
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.
- Trial name
- NCT01431638
- Testing
- Canakinumab 150mg in prefilled syringe
- Where
- 68 sites in United States, Canada and 2 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol.
- Trial name
- NCT01200485
- Testing
- Rasburicase, Allopurinol
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Gout
The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study
Gout is a kind of crystal-associated arthropathy caused by monosodium urate deposition, which is directly related to hyperuricemia caused by purine metabolic disorder and/or decreased uric acid excretion.
- Trial name
- INITIAL (NCT04213534)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease)
Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients. 2.
- Conditions
- Hyperuricemia, NAFLD (Nonalcoholic Fatty Liver Disease), Liver Fibrosis
- Trial name
- NCT07168551
- Testing
- *Lab Methods:* 1- Serum Uric Acid levels 2-Liver Function Tests 3- Lipid Profile . 4- Haemoglobin A1c level . 5- Serum glucose level ., *Imaging Studies:* 1- Ultrasound 2 - FibroScan, Instruments:* 1- *Automated Analyzers*: Used for blood tests, such as serum uric acid and liver function tests.
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Assiut University
Joint Damage
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
- Trial name
- NCT01078389
- Testing
- Febuxostat
- Where
- 56 sites in United States
- Volunteers
- 314 people
- Sponsor
- Takeda
Hyperuricemia, Metabolic Syndrome
Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left ventricular diastolic dysfunction in individuals with metabolic syndrome.
- Conditions
- Hyperuricemia, Metabolic Syndrome, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT03534037
- Testing
- Febuxostat 40 mg, Benzbromarone 50mg, Control
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Defense Medical Center, Taiwan
Hyperuricemia, Gout
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
- Trial name
- NCT01416402
- Testing
- Arhalofenate, Febuxostat, Colchicine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Gilead Sciences
Hyperuricemia
ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
The purpose of this study is to evaluate the safety of ALLN-346 in healthy volunteers, in this first in human, single ascending dose study. ALLN-346 is an enzyme that degrades urate in the gastrointestinal tract.
- Trial name
- SAD (NCT04236219)
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Allena Pharmaceuticals
Coronary Artery Disease, Hyperuricemia
The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA）
The deleterious effects of hyperuricemia (HUA) on cardiovascular disease (CVD) were well established. Aspirin is the most commonly prescribed antiplatelet agent for primary or secondary prophylaxis of CVD.
- Trial name
- AURORA (NCT03691688)
- Testing
- Aspirin 100 mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Gout
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
- Trial name
- NCT02063997
- Testing
- Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 248 people
- Sponsor
- Gilead Sciences
Hyperuricemia, Chronic Renal Disease
Effect of Hyperuricaemia on Chronic Renal Disease
To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention
- Trial name
- NCT03425708
- Testing
- 20mg Febuxostat, 40mg Febuxostat
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Trauma, Inflammation
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
The goal of this project, is to better understand the fluctuation of the level of uric acid in traumatized patients by making serial measurements during their hospitalization in the intensive care unit.
- Trial name
- NCT03622632
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Obesity, Chronic Kidney Disease
FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).
Fructose intake from added sugars has increased dramatically over the last century and has recently been implicated as potential contributor to metabolic syndrome, obesity, hypertension, inflammation and kidney disease.
- Conditions
- Obesity, Chronic Kidney Disease, Metabolic Syndrome
- Trial name
- NCT01332526
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Collegium Medicum w Bydgoszczy